Reducing Heroin Consumption During Methadone Treatment and Limitation of Post Treatment Relapses: Two Crucial Public Health Problems

  • J. J. Déglon
Conference paper


In most of Europe, drug addiction has become one of the basic public health issues with a steep rise in delinquency, prostitution, social decline, the sequels of overdoses and the transmission of Aids.

Methadone treatment programs accompanied by a therapeutic contract and psycho-social support constitutes the most effective approach for limiting the risks of addiction, decreasing the frequency of heroin use and maintaining addicts at a good psycho-social level of stability. The results of an evaluation concerning 280 drug addicts in three methadone treatment programs of the Phenix Foundation in Geneva are presented: characteristics of the patients, decrease of heroin use, limitation of the number of arrests and imprisonments, need for an adequate dosage of methadone adapted to the needs of each patient, usefulness of maintaining the methadone dosage at a relatively high level, etc. The problem of weaning from methadone is a crucial matter for therapists. Various statistics indicate that a great majority of patients relapse within the year following the withdrawal from methadone. To limit these relapses it is necessary to wait until patients are perfectly stabilized from the medical, psychological, social, affective and toxicological point of view before encouraging them to wean themselves with a dose reduction of about 2,5% every two weeks and with the possibility to re-adjust the methadone dosage if the need arises.


Methadone Treatment Drug Addiction Methadone Dosage Methadone Maintenance Treatment Methadone Maintenance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ball J C. Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behaviour 29: 214–226, 1988.CrossRefGoogle Scholar
  2. 2.
    Ball J D, Ross A. The effectiveness of methadone maintenance treatment, Springer-Verlag, New York, 1991.Google Scholar
  3. 3.
    Batki S. Treatment of intravenous drug users with AIDS: the role of methadone maintenance. J Psychoactive Drugs 20: 213–216, 1988.PubMedGoogle Scholar
  4. 4.
    Bayer R, Koenigsberg L. Retention rates among methadone patients: an analysis of the New York experience. 1964–1976 International Journal of 16: 33–41, 1981.Google Scholar
  5. 5.
    Briefer J F, Déglon J J. Traitement de méthadone et comportements à risque de transmission HIV. Méd et Hyg 50: 1544–1549, 1992.Google Scholar
  6. 6.
    Caplehorn J R M, Bell J. Methadone dosage and retention of patients in maintenance treatment. The Medical Journal of Australia 154: 195–199, 1991.PubMedGoogle Scholar
  7. 7.
    Cooper J R. Methadone treatment and acquired immuno-deficiency syndrome. J Am Med Assoc 262: 1664–1668, 1989.CrossRefGoogle Scholar
  8. 8.
    Dole V P. Addictive behaviour. Scientific American 243: 138–154, 1980.PubMedCrossRefGoogle Scholar
  9. 9.
    Dole V P. Implications of methadone maintenance for theories of narcotic addiction. J Am Med Assoc 260: 3025–3029, 1988.CrossRefGoogle Scholar
  10. 10.
    Dole V P, Joseph H. Long term outcome of patients treated with methadone maintenance. Ann N Y Acad Sci 311: 181–189, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Dole V P, Kreek M J. Methadone plasma level. Substained by a reservoir of drug in tissue. Proc Natl Acad Sci USA 70: 10, 1973.CrossRefGoogle Scholar
  12. 12.
    Dole V P, Nyswander M E. Methadone maintenance and its implication for theories of narcotic addiction. In: The Addictive State, edited by Wikler A. Williams and Wilkins, Baltimore, 1968, pp 359–366.Google Scholar
  13. 13.
    Dole V P, Nyswander M E, Kreek M J. Narcotic blockade. Arch Intern Med 118: 304–309, 1966.PubMedCrossRefGoogle Scholar
  14. 14.
    Déglon J J. Le traitement à long terme des héroinomanes par la méthadone, Editions Médecine et Hygiène, Geneve, 1982.Google Scholar
  15. 15.
    Hunt G H, Odoroff M E. Follow up study of narcotic drug addicts after hospitalization. Public Health Rep 77: 41–54, 1962.PubMedCrossRefGoogle Scholar
  16. 16.
    Inturrisi C E, Vereley K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 13: 633–637, 1972.PubMedGoogle Scholar
  17. 17.
    Joe G W, Simpson D D. Retention in treatment of drug abusers: 1971–1972 DARP admission. Am J Drug Alcohol Abuse 2: 63–71, 1975.PubMedCrossRefGoogle Scholar
  18. 18.
    Kreek M J. Medical safety and side effects of methadone in tolerant individuals. J Am Med Assoc 223: 665–668, 1973.CrossRefGoogle Scholar
  19. 19.
    Kreek M J. Plasma and urine levels of methadone. N Y State J Med 73: 2773–2777, 1973.PubMedGoogle Scholar
  20. 20.
    Kreek M J. Medical complications in methadone patients. Ann N Y Acad Sci 311: 110–134, 1978.PubMedCrossRefGoogle Scholar
  21. 21.
    Kreek M J. Rationale for maintenance pharmacotherapy of opiate dependence. In: Addictive States, edited by O’Brien C P, Jaffe J H. Raven Press, New York, 1992, pp 205–230.Google Scholar
  22. 22.
    Mino A. Analyse scientifique de la littérature sur la remise controlée d’héroine ou de morphine, OFSP, Berne, 1990.Google Scholar
  23. 23.
    Newman R G. Narcotic addiction and methadone treatment in Hong Kong: Lessons for the United States. J Public Health Policy 6: 526–538, 1985.PubMedCrossRefGoogle Scholar
  24. 24.
    Novick D M, Joseph H, Croxson T S. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 150: 97–99, 1990.PubMedCrossRefGoogle Scholar
  25. 25.
    Simpson D D, Savage L V, Lloyd M R. Follow up evaluation of drug abuse during 1969 to 1972. Archives of General Psychiatry 36: 772–780, 1979.PubMedGoogle Scholar
  26. 26.
    Stimmel B, Goldberg J, Cohen M, Rotkopf E. Detoxication from methadone maintenance: Risk factors associated with relapse to narcotic use. Ann N Y Acad Sci 311: 173–180, 1978.PubMedCrossRefGoogle Scholar
  27. 27.
    Zweben J E, Payte J T. Methadone maintenance in the treatment of opioid dependence: A current perspective. The West Journ of Med 152 (T): 588–599, 1990.Google Scholar

Copyright information

© Springer-Verlag Wien 1995

Authors and Affiliations

  • J. J. Déglon
    • 1
  1. 1.The Phenix FoundationGenevaSuisse

Personalised recommendations